Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU)

References

• Centers for Disease Control and Prevention. Active bacterial core surveillance (ABCs) report: Streptococcus pneumoniae, 2018. 2018 [accessed 2020 July 23]. https://www.cdc.gov/abcs/reports-findings/survreports/spneu17.html .
   Google Scholar
• European Centre for Disease Prevention and Control. Invasive pneumococcal disease. Annual epidemiological report for 2018. 2018 [accessed 2020 Sept 14]. https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2018_IPD.pdf .
   Google Scholar
• European Centre for Disease Prevention and Control. Seasonal influenza 2018–2019. Annual epidemiological report. 2019 [accessed 2020 Nov 7]. https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2018_seasonal-influenza-corrected.pdf .
   Google Scholar
• Xu X, Blanton L, Elal AIA, Alabi N, Barnes J, Biggerstaff M, Brammer L, Budd AP, Burns E, Cummings CN, et al. Update: influenza activity in the United States during the 2018-19 season and composition of the 2019-20 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2019;68:544–51. doi:10.15585/mmwr.mm6824a3.
   PubMed Web of Science ®Google Scholar
• Kristensen M, van Lier A, Eilers R, McDonald SA, Opstelten W, Van Der Maas N, van der Hoek W, Kretzschmar ME, Nielen MM, de Melker HE. Burden of four vaccine preventable diseases in older adults. Vaccine. 2016;34:942–49. doi:10.1016/j.vaccine.2015.12.052.
   PubMed Web of Science ®Google Scholar
• Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2014;20(Suppl 5):45–51. doi:10.1111/1469-0691.12461.
   PubMed Web of Science ®Google Scholar
• Sullivan SG, Price OH, Regan AK. Burden, effectiveness and safety of influenza vaccines in elderly, paediatric and pregnant populations. Ther Adv Vaccines Immunother. 2019;7:2515135519826481. doi:10.1177/2515135519826481.
   Google Scholar
• Walter ND, Taylor TH, Shay DK, Thompson WW, Brammer L, Dowell SF, Moore MR, Active Bacterial Core Surveillance Team. Influenza circulation and the burden of invasive pneumococcal pneumonia during a non-pandemic period in the United States. Clin Infect Dis. 2010;50:175–83. doi:10.1086/649208.
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Harboe ZB, Viboud C, Krause TG, Miller M, Molbak K, Konradsen HB. Pneumococcal disease seasonality: incidence, severity and the role of influenza activity. Eur Respir J. 2014;43:833–41. doi:10.1183/09031936.00056813.
   PubMed Web of Science ®Google Scholar
• Gilchrist SA, Nanni A, Levine O. Benefits and effectiveness of administering pneumococcal polysaccharide vaccine with seasonal influenza vaccine: an approach for policymakers. Am J Public Health. 2012;102:596–605. doi:10.2105/AJPH.2011.300512.
   PubMed Web of Science ®Google Scholar
• Dominguez A, Soldevila N, Toledo D, Torner N, Force L, Perez MJ, Martin V, Rodriguez-Rojas L, Astray J, Egurrola M, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccination in preventing community-acquired pneumonia hospitalization and severe outcomes in the elderly in Spain. PLoS One. 2017;12:e0171943. doi:10.1371/journal.pone.0171943.
   PubMed Web of Science ®Google Scholar
• Yin M, Huang L, Zhang Y, Yu N, Xu X, Liang Y, Ni J. Effectiveness and safety of dual influenza and pneumococcal vaccination versus separate administration or no vaccination in older adults: a meta-analysis. Expert Rev Vaccines. 2018;17:653–63. doi:10.1080/14760584.2018.1495077.
   PubMed Web of Science ®Google Scholar
• Zhang YY, Tang XF, Du CH, Wang BB, Bi ZW, Dong BR. Comparison of dual influenza and pneumococcal polysaccharide vaccination with influenza vaccination alone for preventing pneumonia and reducing mortality among the elderly: a meta-analysis. Hum Vaccin Immunother. 2016;12:3056–64. doi:10.1080/21645515.2016.1221552.
   PubMed Web of Science ®Google Scholar
• Robert Koch-Institut. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut– 2017/2018. 2017 accessed 2020 Mar 19]. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2017/Ausgaben/34_17.pdf?__blob=publicationFile .
   Google Scholar
• Australian Immunisation Handbook. Pneumococcal disease. 2020 [accessed 2020 Aug 3]. https://immunisationhandbook.health.gov.au/vaccine-preventable-diseases/pneumococcal-disease .
   Google Scholar
• World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2020 global summary. 2020 accessed 2020 Nov 7]. https://apps.who.int/immunization_monitoring/globalsummary/schedules .
   Google Scholar
• Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >/=65 years: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68:1069–75. doi:10.15585/mmwr.mm6846a5.
   PubMed Web of Science ®Google Scholar
• Varghese J, Chochua S, Tran T, Walker H, Li Z, Snippes Vagnone PM, Lynfield R, McGee L, Li Y, Metcalf BJ, et al. Multistate population and whole genome sequence-based strain surveillance of invasive pneumococci recovered in the USA during 2017. Clin Microbiol Infect. 2020;26:512e1- e10. doi:10.1016/j.cmi.2019.09.008.
   Web of Science ®Google Scholar
• Rupp R, Hurley D, Grayson S, Li J, Nolan K, McFetridge RD, Hartzel J, Abeygunawardana C, Winters M, Pujar H, et al. A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Hum Vaccin Immunother. 2019;15:549–59. doi:10.1080/21645515.2019.1568159.
   PubMed Web of Science ®Google Scholar
• Balsells E, Dagan R, Yildirim I, Gounder PP, Steens A, Munoz-Almagro C, Mameli C, Kandasamy R, Givon Lavi N, Daprai L, et al. The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: a systematic review and meta-analysis. J Infect. 2018;77:368–78. doi:10.1016/j.jinf.2018.06.004.
   PubMed Web of Science ®Google Scholar
• Adam HJ, Golden AR, Karlowsky JA, Baxter MR, Nichol KA, Martin I, Demczuk W, Mulvey MR, Gilmour MW, Hoban DJ, et al. Analysis of multidrug resistance in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011–15. J Antimicrob Chemother. 2018;73:vii12–vii9. doi:10.1093/jac/dky158.
   PubMed Web of Science ®Google Scholar
• Stacey HL, Rosen J, Peterson JT, Williams-Diaz A, Gakhar V, Sterling TM, Acosta CJ, Nolan KM, Li J, Pedley A, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. Hum Vaccin Immunother. 2019;15:530–39. doi:10.1080/21645515.2018.1532249.
   PubMed Web of Science ®Google Scholar
• Ermlich SJ, Andrews CP, Folkerth S, Rupp R, Greenberg D, McFetridge RD, Hartzel J, Marchese RD, Stek JE, Abeygunawardana C, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults ≥50 years of age. Vaccine. 2018;36:6875–82. doi:10.1016/j.vaccine.2018.03.012.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Vaccination coverage among adults in the United States, National Health Interview Survey, 2017. 2018 [accessed 2020 Sept 7]. https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/NHIS-2017.html .
   Google Scholar
• Song JY, Cheong HJ, Hyun HJ, Seo YB, Lee J, Wie SH, Choi MJ, Choi WS, Noh JY, Yun JW, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in 60-year-old adults. Vaccine. 2017;35:313–20. doi:10.1016/j.vaccine.2016.11.047.
   PubMed Web of Science ®Google Scholar
• Frenck RW Jr., Gurtman A, Rubino J, Smith W, van Cleeff M, Jayawardene D, Giardina PC, Emini EA, Gruber WC, Scott DA, et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol. 2012;19:1296–303. doi:10.1128/CVI.00176-12.
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Flamaing J, Rumke HC, Penzes J, Juergens C, Wenz A, Jayawardene D, Giardina P, Emini EA, Gruber WC, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged >/=65 years. Vaccine. 2011;29:5195–202. doi:10.1016/j.vaccine.2011.05.031.
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Schmoele-Thoma B. Assessment of functional antibacterial opsonophagocytic antibodies elicited by 13-valent pneumococcal conjugate vaccine administered concomitantly with trivalent influenza vaccine in a randomized clinical trial in adults aged >/=65 years. Vaccine. 2013;31:291–94. doi:10.1016/j.vaccine.2012.10.077.
   PubMed Web of Science ®Google Scholar
• Thompson AR, Klein NP, Downey HJ, Patterson S, Sundaraiyer V, Watson W, Clarke K, Jansen KU, Sebastian S, Gruber WC, et al. Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial. Hum Vaccin Immunother. 2019;15:444–51. doi:10.1080/21645515.2018.1533777.
   PubMed Web of Science ®Google Scholar
• Ofori-Anyinam O, Leroux-Roels G, Drame M, Aerssens A, Maes C, Amanullah A, Schuind A, Li P, Jain VK, Innis BL. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults >/=50 years of age: results from a phase III, randomized, non-inferiority trial. Vaccine. 2017;35:6321–28. doi:10.1016/j.vaccine.2017.09.012.
   PubMed Web of Science ®Google Scholar
• Nakashima K, Aoshima M, Ohfuji S, Yamawaki S, Nemoto M, Hasegawa S, Noma S, Misawa M, Hosokawa N, Yaegashi M, et al. Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: a randomized, open-label, non-inferiority trial. Hum Vaccin Immunother. 2018;14:1923–30. doi:10.1080/21645515.2018.1455476.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 2007 [accessed 2021 Jan 29]. https://www.fda.gov/media/73679/download .
   Google Scholar
• Nolan KM, Bonhomme ME, Schier CJ, Green T, Antonello JM, Murphy RD. Optimization and validation of a microcolony multiplexed opsonophagocytic killing assay for 15 pneumococcal serotypes. Bioanalysis. 2020;12:1003–20. doi:10.4155/bio-2020-0024.
   PubMed Web of Science ®Google Scholar
• Nolan KM, Zhang Y, Antonello JM, Howlett AH, Bonhomme CJ, Greway R, Green T, Gorguette d’Argoeuves P, Goldblatt D, Murphy RD. Enhanced antipneumococcal antibody electrochemiluminescence assay: validation and bridging to the WHO reference ELISA. Bioanalysis. 2020;12:1363–75. doi:10.4155/bio-2020-0023.
   PubMed Web of Science ®Google Scholar
• Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213–26. doi:10.1002/sim.4780040211.
   PubMed Web of Science ®Google Scholar
• Liang K-Y, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankhya: The Indian Journal of Statistics. 2000;62:134–48.
   Google Scholar
• Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26:404–13. doi:10.1093/biomet/26.4.404.
   Web of Science ®Google Scholar
• Peterson JT, Stacey HL, MacNair JE, Li J, Hartzel JS, Sterling TM, Benner P, Tamms GM, Musey LK. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Hum Vaccin Immunother. 2019;15:540–48. doi:10.1080/21645515.2018.1532250.
   PubMed Web of Science ®Google Scholar
• Frenck RW Jr., Fiquet A, Gurtman A, van Cleeff M, Davis M, Rubino J, Smith W, Sundaraiyer V, Sidhu M, Emini EA, et al. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. Vaccine. 2016;34:3454–62. doi:10.1016/j.vaccine.2016.04.093.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine. 2013;31:3594–602. doi:10.1016/j.vaccine.2013.04.084.
   PubMed Web of Science ®Google Scholar
• Aspinall R, Del Giudice G, Effros RB, Grubeck-Loebenstein B, Sambhara S. Challenges for vaccination in the elderly. Immun Ageing. 2007;4:9. doi:10.1186/1742-4933-4-9.
   PubMedGoogle Scholar
• Krone CL, van de Groep K, Trzcinski K, Sanders EA, Bogaert D. Immunosenescence and pneumococcal disease: an imbalance in host-pathogen interactions. Lancet Respir Med. 2014;2:141–53. doi:10.1016/S2213-2600(13)70165-6.
   PubMed Web of Science ®Google Scholar